Needham & Company Defends AMAG Pharmaceuticals (AMAG), Says Buy On Weakness
Tweet Send to a Friend
Needham & Company commented on AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG), which is lower today on concerns about Feraheme's benefit versus ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
